Literature DB >> 2135382

Autoantibodies to GABA-ergic neurons and pancreatic beta cells in stiff-man syndrome.

M Solimena1, F Folli, R Aparisi, G Pozza, P De Camilli.   

Abstract

Stiff-man syndrome is a rare disorder of the central nervous system of unknown pathogenesis. We have previously reported the presence of autoantibodies against glutamic acid decarboxylase (GAD) in a patient with stiff-man syndrome, epilepsy, and insulin-dependent diabetes mellitus. GAD is an enzyme selectively concentrated in neurons secreting the neurotransmitter gamma-aminobutyric acid (GABA) and in pancreatic beta cells. We subsequently observed autoantibodies to GABA-ergic neurons in 20 of 33 patients with stiff-man syndrome. GAD was the principal autoantigen. In the group of patients positive for autoantibodies against GABA-ergic neurons, there was a striking association with organ-specific autoimmune diseases, primarily insulin-dependent diabetes mellitus. These findings support the hypothesis that stiff-man syndrome is an autoimmune disease and suggest that GAD is the primary autoantigen involved in stiff-man syndrome and the associated insulin-dependent diabetes mellitus. Our findings also indicate that autoantibodies directed against GABA-ergic neurons are a useful marker in the diagnosis of the disease.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2135382     DOI: 10.1056/NEJM199005313222202

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  125 in total

1.  Stiff-man syndrome.

Authors:  H U Rehman
Journal:  Postgrad Med J       Date:  1998-11       Impact factor: 2.401

2.  Stiff-man syndrome in childhood.

Authors:  V Markandeyulu; T P Joseph; T Solomon; J Jacob; S Kumar; C Gnanamuthu
Journal:  J R Soc Med       Date:  2001-06       Impact factor: 5.344

3.  Biography of Pietro De Camilli.

Authors:  Liza Bundesen
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-24       Impact factor: 11.205

Review 4.  Autoimmune stiff person syndrome and related myelopathies: understanding of electrophysiological and immunological processes.

Authors:  Goran Rakocevic; Mary Kay Floeter
Journal:  Muscle Nerve       Date:  2012-05       Impact factor: 3.217

5.  Central nervous system destruction mediated by glutamic acid decarboxylase-specific CD4+ T cells.

Authors:  Amanda R Burton; Zachary Baquet; George S Eisenbarth; Roland Tisch; Richard Smeyne; Creg J Workman; Dario A A Vignali
Journal:  J Immunol       Date:  2010-03-26       Impact factor: 5.422

6.  Characterization of CD4+ T cells specific for glutamic acid decarboxylase (GAD65) and proinsulin in a patient with stiff-person syndrome but without type 1 diabetes.

Authors:  Arno Hänninen; Merja Soilu-Hänninen; Christiane S Hampe; Angie Deptula; Kelly Geubtner; Jorma Ilonen; Mikael Knip; Helena Reijonen
Journal:  Diabetes Metab Res Rev       Date:  2010-05       Impact factor: 4.876

7.  Comments on Kristensen et al.: Clinical value of FDG-PET/CT in suspected paraneoplastic syndromes: a retrospective analysis of 137 patients.

Authors:  Betül Vatankulu; Sabire Yilmaz Aksoy; Sait Sager; Metin Halaç
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-12-15       Impact factor: 9.236

8.  Specific phobia is a frequent non-motor feature in stiff man syndrome.

Authors:  P Henningsen; H-M Meinck
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-04       Impact factor: 10.154

9.  Autoreactive epitopes defined by diabetes-associated human monoclonal antibodies are localized in the middle and C-terminal domains of the smaller form of glutamate decarboxylase.

Authors:  W Richter; Y Shi; S Baekkeskov
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-01       Impact factor: 11.205

Review 10.  Trials in type 1 diabetes: Antigen-specific therapies.

Authors:  Ken T Coppieters; Leonard C Harrison; Matthias G von Herrath
Journal:  Clin Immunol       Date:  2013-02-15       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.